ACCESS Newswire
25 Jan 2023, 01:35 GMT+10
ZURICH, SWITZERLAND / ACCESSWIRE / January 24, 2023 / InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces the appointment of Dr. Christopher Prior as Chief Executive Officer. In his new role, Dr. Prior will be responsible for leading the company into its next stage of development and global expansion.
Dr. Christopher Prior is a highly accomplished serial entrepreneur who has built numerous biotechnology companies creating extensive value for the investors and stakeholders. Over the course of his 30+ year career, he has generated more than 25 Investigational New Drugs (INDs) and achieved four product approvals. In addition, he founded, built and sold two companies (Principia, BioRexis) in deal value exceeding $550M. More recently, Dr. Prior successfully took a company public and significantly increased shareholder value by achieving milestones on time and on budget. Dr. Prior has held senior management positions all in product development at Aventis (now Sanofi), Pfizer, Human Genome Sciences (now GSK) and Biogen. Dr. Prior received a B.Sc. (honors) in chemistry from the University of London, a Ph.D. in biochemistry from Columbia University in New York City and a research fellowship at The Rockefeller Medical Institute.
'InterAx has a unique biosystems approach integrated into artificial intelligence (AI) to decipher cellular response and create novel drugs with high efficacy and safety. I am impressed with the advances the company has made in unlocking new drug targets with improved pharmacology', Dr. Prior noted. 'Developing small orally available cost-effective molecules with same functional effect as peptides, proteins and monoclonal antibodies requiring frequent injections is nothing short of a huge game changer', added Dr. Prior.
'We are delighted to have Dr. Prior join our team, especially at a time when our platform has discovered a unique chemokine receptor interaction being evaluated in vivo to treat a highly aggressive and difficult to treat form of breast cancer. This validation will take the company into its next stage of development. To our knowledge, no other AI approach to drug discovery addresses both cellular signaling and drug-target interaction, a critical link needed for effective drug discovery. Dr. Prior's experience in product development and business operations provides a perfect fit with our innovative team of cell biologists and computational scientists', noted Dr. Aurélien Rizk, InterAx CSO and Co-Founder.
InterAx Biotech AG
The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in G Protein-Coupled Receptor (GPCR) drug discovery and covers hit-generation, hit-to-lead and lead optimization for all targets including orphan GPCRs. InterAx has a highly experienced and dedicated team of scientists specialized in AI, mathematical models of signaling pathways, cellular pharmacology and computational chemistry. The company is currently funded by lead institutional investors and a grant from the EU commission and is preparing for the next round of financing to grow its capabilities and advance lead drug candidates.
For more information, please visit linkedin.com/company/interax-biotech | www.interaxbiotech.com
Media contact: Luca Zenone, [email protected]
SOURCE: InterAx Biotech AG
Get a daily dose of Cleveland Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Cleveland Star.
More InformationNEW YORK, New York - U.S. stock markets closed firmly in positive territory to start the week Monday, with the S&P 500 and Dow Jones...
WASHINGTON, D.C.: On Friday, President Donald Trump announced that he was halting trade discussions with Canada due to its decision...
LONDON, U.K.: A little-known investment fund based in the United Arab Emirates has emerged as the most prominent public backer of U.S....
SAN FRANCISCO, California: Across the U.S., a growing number of people are taking obesity treatment into their own hands — literally....
SAN FRANCISCO, California: Under pressure from European regulators, Apple has revamped its App Store policies in the EU, introducing...
NEW YORK CITY, New York: The U.S. dollar tumbled this week, hitting its lowest levels since 2021 against the euro, British pound, and...
ABU DHABI, 19th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has become the first and only research hospital in the UAE to receive...
ABU DHABI, 17th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion...
ABU DHABI, 9th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has successfully performed the UAE's first robotic cytoreductive surgery...
ABU DHABI,16th May, 2025 (WAM) - Oracle Health, Cleveland Clinic, and G42 today announced a strategic partnership to develop a groundbreaking...
ABU DHABI, 6th May, 2025 (WAM) -- PureHealth and its subsidiary SEHA have partnered with the number one US children's hospital, Cincinnati...
Argentinian composer Lalo Schifrin, the genre-blending film and television composer behind the Mission: Impossible, Bullitt, and Cool...